Question 1

What is SELLAS Life Sciences Group's P/B ratio?

Accepted Answer

SELLAS Life Sciences Group (SLS) P/B ratio is 17.4× as of July 27, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for SELLAS Life Sciences Group?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For SELLAS Life Sciences Group specifically, the relevant sector benchmark is the current sector median of 3.2×.

Question 5

Is SELLAS Life Sciences Group's P/B ratio high or low?

Accepted Answer

SELLAS Life Sciences Group's P/B ratio of 17.4× is above its own 5-year average of 7.8× and above the sector median of 3.2×. That places the current reading at the 93th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is SELLAS Life Sciences Group's historical P/B ratio range?

Accepted Answer

In the available daily series, SELLAS Life Sciences Group (SLS) P/B ratio has ranged from a low of 0.0× in 2016 to a high of 1019.7× in 2009. The 5-year average is 7.8× and the 5-year median is 5.4×.

Question 7

What was SELLAS Life Sciences Group's P/B ratio in 2025?

Accepted Answer

SELLAS Life Sciences Group (SLS) P/B ratio at the end of 2025 was 8.1×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does SELLAS Life Sciences Group's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$577M	$70.9M	8.1×	+0.0×	Dec 31, 2025
2024	$76.9M	$9.47M	8.1×	—	Dec 31, 2024
2023	$32.7M	-$7.98M	—	—	Dec 31, 2023
2022	$49.1M	$4.85M	10.1×	+5.8×	Dec 31, 2022
2021	$87.9M	$20.3M	4.3×	+2.2×	Dec 31, 2021
2020	$60.3M	$28M	2.2×	-1.2×	Dec 31, 2020
2019	$20.7M	$6.09M	3.4×	-1.7×	Dec 31, 2019
2018	$26.8M	$5.25M	5.1×	-15.0×	Dec 31, 2018
2017	$41.7M	$2.07M	20.2×	+17.6×	Dec 31, 2017
2016	$72.8M	$28.7M	2.5×	-156.0×	Dec 31, 2016
2015	$2.14B	$13.5M	158.5×	+113.4×	Dec 31, 2015
2014	$1.67B	$37.1M	45.1×	-836.4×	Dec 31, 2014
2013	$5.19B	$5.89M	881.4×	+840.3×	Dec 31, 2013
2012	$1.14B	$27.8M	41.2×	+21.1×	Dec 31, 2012
2011	$203M	$10.1M	20.1×	-216.7×	Dec 31, 2011
2010	$575M	$2.43M	236.8×	-782.9×	Dec 31, 2010
2009	$756M	$741K	1019.7×	+940.4×	Dec 31, 2009
2008	$711M	$8.97M	79.3×	-30.8×	Dec 31, 2008
2007	$1.19B	$10.8M	110.1×	—	Dec 31, 2007


Charles River (CRL)	2.6×
Danaher (DHR)	2.6×
Spruce Biosciences (SPRB)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Solventum (SOLV)	2.3×
Medtronic (MDT)	2.2×
Elevance Health (ELV)	1.9×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Zimmer Biomet Holdings (ZBH)	1.4×
Revvity (RVTY)	1.4×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Ovid Therapeutics (OVID)	0.8×
Centene (CNC)	0.8×
Teladoc Health (TDOC)	0.7×

P/B Ratio for SELLAS Life Sciences Group (SLS) 2007-2026

P/B Ratio daily chart for SELLAS Life Sciences Group (SLS)

Historical P/B Ratio for SELLAS Life Sciences Group (SLS) from 2007 to 2025

About P/B Ratio at SELLAS Life Sciences Group (SLS)

SELLAS Life Sciences Group P/B Ratio by Year

SELLAS Life Sciences Group P/B Ratio 2025: 8.1×

SELLAS Life Sciences Group P/B Ratio 2024: 8.1×

SELLAS Life Sciences Group P/B Ratio 2022: 10.1×

SELLAS Life Sciences Group P/B Ratio 2021: 4.3×

SELLAS Life Sciences Group P/B Ratio 2020: 2.2×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

SELLAS Life Sciences Group (SLS) Key Financials